હોમ › મલ્ટિપલ માયલોમા › ટેક્સાસ › Houston
Houston, TX માં મલ્ટિપલ માયલોમા ક્લિનિકલ ટ્રાયલ્સ
Houston (લગભગ 30 માઇલની અંદર) ની સાઇટ્સ પર મલ્ટિપલ માયલોમા માટે 38 અભ્યાસો ભાગીદારો શોધી રહ્યા છે. કોઈ અભ્યાસ ખોલો અને જુઓ કે કોઈ જોડાઈ શકે છે અને અભ્યાસ ટીમ સાથે સંપર્ક કેવી રીતે કરવો.
અધિકૃત અભ્યાસ ટેક્સ્ટ (અંગ્રેજી)
અહીં અભ્યાસ માટે ભરતી કરી રહ્યા છો? આ પેજની ટોચ પર તેને ફીચર કરો — 30 દિવસ માટે $99 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
ભરતી ચાલુ છેફેઝ 3
- Research Site, Houston
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
ભરતી ચાલુ છેફેઝ 1
- MD Anderson Cancer Center, Houston
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
ભરતી ચાલુ છેફેઝ 1
- Research Site, Houston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 3
- MD Anderson Cancer Center, Houston
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1/2
- MD Anderson, Houston
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
ભરતી ચાલુ છેફેઝ 3
- Houston Methodist Hospital, Houston
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
ભરતી ચાલુ છેફેઝ 3
- The University of Texas MD Anderson Cancer Center, Houston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
ભરતી ચાલુ છેફેઝ 4
- MD Anderson Cancer Center, Houston
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- Oncology Consultants (P1 Trials -Exigent Network), Houston
- Lumi Research, Houston
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ભરતી ચાલુ છેફેઝ 2
- The University of Texas MD Anderson Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ભરતી ચાલુ છેફેઝ 3
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
ભરતી ચાલુ છેફેઝ 2
- MD Anderson Cancer Center, Houston
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1/2
- MD Anderson Cancer Center, Houston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
ભરતી ચાલુ છેફેઝ 3
- University of Texas MD Anderson Cancer Center, Houston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1/2
- Research Site, Houston
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
ભરતી ચાલુ છેફેઝ 3
- Houston Methodist Cancer Center Infusion, Houston
- Houston Methodist Hospital - Department of Pharmacy, Houston
- Houston Methodist Hospital Cancer Center, Houston
- અને 3 વધુ
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
ભરતી ચાલુ છેફેઝ 1/2
- MD Anderson Cancer Center, Houston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ભરતી ચાલુ છેફેઝ 1/2
- Research Site, Houston
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
ભરતી ચાલુ છેફેઝ 2સ્વસ્થ સ્વેચ્છાએ ભાગ લેનારા સ્વાગત છે
- MD Anderson Cancer Center, Houston
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
ભરતી ચાલુ છેફેઝ 3
- Research Site, Houston
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
ભરતી ચાલુ છેફેઝ 1
- Houston Methodist Hospital, Houston
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1/2
- M D Anderson Cancer Center, Houston
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
ભરતી ચાલુ છેફેઝ 2
- MD Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
ભરતી ચાલુ છેફેઝ 1/2
- M D Anderson Cancer Center, Houston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- University of Texas MD Anderson Cancer Center, Houston
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- Oncology Consultants /ID# 268323, Houston
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
ભરતી ચાલુ છેફેઝ 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- M D Anderson Cancer Center, Houston
- અને 2 વધુ
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
ભરતી ચાલુ છેફેઝ 2
- M D Anderson Cancer Center, Houston
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
ભરતી ચાલુ છેફેઝ 3
- Houston Methodist Hospital, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસ
- M D Anderson Cancer Center, Houston
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
ભરતી ચાલુ છેફેઝ 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
ભરતી ચાલુ છેફેઝ 1
- MD Anderson Cancer Center, Houston
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 2
- M D Anderson Cancer Center, Houston
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
ભરતી ચાલુ છેફેઝ 1/2
- Houston Methodist Neal Cancer Center, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ભરતી ચાલુ છેફેઝ 1/2
- MDACC, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
ભરતી ચાલુ છેફેઝ 1/2
- University of Texas MD Anderson Cancer Center, Houston
અન્ય શહેરોમાં મલ્ટિપલ માયલોમા ટ્રાયલ્સ
- New York City, NY60 અભ્યાસો
- Boston, MA42 અભ્યાસો
- Atlanta, GA41 અભ્યાસો
- Durham, NC37 અભ્યાસો
- Nashville, TN32 અભ્યાસો
- Denver, CO27 અભ્યાસો
- Rochester, MN24 અભ્યાસો
- St. Louis, MO24 અભ્યાસો
- Columbus, OH24 અભ્યાસો
- Baldwin Park, CA23 અભ્યાસો
- Chicago, IL22 અભ્યાસો
- Seattle, WA22 અભ્યાસો
Houston માં અન્ય અભ્યાસો
- નોન-સ્મોલ સેલ લંગ કેન્સર145 અભ્યાસો
- સ્તન કેન્સર126 અભ્યાસો
- કેન્સર (બધા પ્રકાર)121 અભ્યાસો
- મેટાસ્ટેટિક કેન્સર104 અભ્યાસો
- કોલોરેક્ટલ કેન્સર102 અભ્યાસો
- ઓવેરિયન કેન્સર89 અભ્યાસો
- એક્યુટ માયલોઇડ લ્યુકેમિયા85 અભ્યાસો
- ફેફસાનું કેન્સર78 અભ્યાસો
- પ્રોસ્ટેટ કેન્સર76 અભ્યાસો
- એન્ડોમેટ્રિયલ કેન્સર68 અભ્યાસો
- પેન્ક્રિએટિક કેન્સર61 અભ્યાસો
- મેલેનોમા59 અભ્યાસો
ClinicalTrials.gov પરથી, તારીખ 5 ઑક્ટો, 2026 ના ડેટા સાથે. દરેક અભ્યાસની પોતાની પાત્રતા શરતો હોય છે; અભ્યાસ ટીમ નક્કી કરે છે કે કોઈ જોડાઈ શકે છે કે નહીં.